Clinical Trial Update: HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update comparing HR070803 with Oxaliplatin and S-1 versus NALIRIFOX as adjuvant therapy for pancreatic cancer; the study status is not ye…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• HR070803
• NALIRIFOX (liposomal irinotecan + 5-fluorouracil/leucovorin)
• OXALIPLATIN (Oxaliplatin)
• S-1 (tegafur/gimeracil/oteracil)

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Efficacy and Safety | Phase 2 | Status: NOT_YET_RECRUITING